LAVA Therapeutics NV - Asset Resilience Ratio
LAVA Therapeutics NV (LVTX) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check LVTX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how LAVA Therapeutics NV's Asset Resilience Ratio has changed over time. See LAVA Therapeutics NV (LVTX) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down LAVA Therapeutics NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LVTX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LAVA Therapeutics NV maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
LAVA Therapeutics NV Industry Peers by Asset Resilience Ratio
Compare LAVA Therapeutics NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for LAVA Therapeutics NV (2019–2024)
The table below shows the annual Asset Resilience Ratio data for LAVA Therapeutics NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 51.42% | $41.56 Million | $80.83 Million | +0.94pp |
| 2023-12-31 | 50.48% | $51.34 Million | $101.71 Million | +27.79pp |
| 2022-12-31 | 22.68% | $32.53 Million | $143.43 Million | -7.72pp |
| 2021-12-31 | 30.40% | $42.33 Million | $139.25 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $20.49 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $8.80 Million | -- |
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more